Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells
NCT03535246 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2026-04-24
Summary
The primary objectives are to evaluate the safety and efficacy of infusion of autologous tumor associated antigen-specific engineered immune effector cells (EIE).
Conditions
Interventions
- BIOLOGICAL
-
Engineered Immune Cells
Engineered immune effector cells (EIE)
Sponsors & Collaborators
-
Shenzhen Geno-Immune Medical Institute
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 1 Year
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-07-01
- Primary Completion
- 2028-06-30
- Completion
- 2029-12-31
Countries
- China
Study Locations
More Related Trials
-
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
NCT02318394 ·Status: COMPLETED ·Phase: PHASE1
-
Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors
NCT05235607 ·Status: UNKNOWN ·Phase: PHASE1
-
Immunotherapy & Me
NCT03347058 ·Status: COMPLETED ·Phase: NA
-
Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors
NCT04765462 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors
NCT03047811 ·Status: UNKNOWN ·Phase: NA
-
Autologous Natural Killer T Cells Infusion for the Treatment of Cancer
NCT01801852 ·Status: UNKNOWN ·Phase: NA
-
A Study in Adult Subjects With Select Advanced Solid Tumors
NCT02583165 ·Status: COMPLETED ·Phase: PHASE1
-
Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma
NCT07123545 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy
NCT03434912 ·Status: UNKNOWN
-
Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer
NCT01637805 ·Status: UNKNOWN ·Phase: PHASE1
-
Neoantigen-expanded Autologous Immune Cell Therapy
NCT05020119 ·Status: UNKNOWN ·Phase: PHASE1
-
a Single-arm, Single-center, Open Clinical Study
NCT06431100 ·Status: RECRUITING
-
Prostate Cancer Vaccines
NCT07068555 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
NCT06089967 ·Status: COMPLETED
-
Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer
NCT02496273 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
CX3CR1+T Cell Predict Immunotherapy Efficacy
NCT06054152 ·Status: COMPLETED
-
A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19
NCT04324996 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer.
NCT02602249 ·Status: UNKNOWN ·Phase: PHASE1
-
NK Cells Infusion for Advanced Malignancies
NCT03619954 ·Status: UNKNOWN ·Phase: PHASE1
-
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
NCT01906632 ·Status: COMPLETED ·Phase: NA
-
Engineered Dendritic Cell Vaccines for Multiple Myeloma
NCT06435910 ·Status: RECRUITING ·Phase: PHASE1
-
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
NCT05976906 ·Status: UNKNOWN ·Phase: PHASE1
-
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
NCT05620342 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
NCT03778814 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients
NCT02766348 ·Status: UNKNOWN ·Phase: PHASE2